

## Contents

**Foreword** *xvii*

**About the Editors** *xix*

**List of Abbreviations** *xxi*

- 1 Biopharmaceutical Innovation at a Glance** *1*  
*Markus Hinder, Dominik Hartl, and Alexander Schuhmacher*  
Summary *1*
- 1.1 Biopharmaceutical Innovation and Drug Development, the Past and Present *2*
- 1.2 Why We Wrote This Book and What Readers Can Expect to Gain from Reading It *4*  
References *5*
- 2 Pharmacology and Drug Targets – The Basis of Therapeutics** *7*  
*Lena Hartl, Martin A. Fink, and Sandra Beer-Hammer*  
Summary *7*
- 2.1 Introduction *8*
- 2.2 Pharmacodynamics *10*
- 2.3 Receptors and Ion Channels *11*
- 2.3.1 G-protein-Coupled Receptors (GPCRs) *11*
- 2.3.2 Ion Channels *12*
- 2.3.3 Enzyme-Associated Receptors *12*
- 2.3.4 Non-receptor-Mediated Effects *14*
- 2.4 Receptor Agonism and Antagonism *15*
- 2.5 Implications for Drug Development *18*
- 2.6 Pharmacokinetics *19*
- 2.6.1 Liberation and Administration *19*
- 2.6.2 Absorption *21*
- 2.6.3 Distribution *21*
- 2.6.4 Metabolism/Biotransformation *22*
- 2.6.5 Phase I Reaction *23*
- 2.6.5.1 Oxidation *23*

2.6.5.2	Reduction and Hydrolysis	24
2.6.5.3	Phase II Reaction	24
2.6.5.4	Phase III Reaction	25
2.6.6	Excretion	25
2.6.6.1	Renal Elimination	25
2.6.6.2	Biliary Elimination	27
2.6.6.3	Intestinal Elimination	27
2.6.6.4	Pulmonary Elimination	27
2.7	Quantitative Pharmacokinetics	27
2.7.1	Dosing Regimen	27
2.7.2	Clearance (CL)	27
2.7.3	Exposure as Area Under the Curve	28
2.7.4	Bioavailability	28
2.7.5	$C_{\max}$ , $C_{\text{trough}}$ , and Peak-to-Trough-Ratio	28
2.7.6	Volume of Distribution	29
2.7.7	Half-Life	29
2.7.8	Accumulation and Loading Dose	29
2.7.9	Induction and Maintenance Dose	30
2.8	Pharmacokinetic Models	30
2.9	Implications for Drug Development	31
2.9.1	PK/PD Modelling	31
2.9.2	Characteristics of Pharmacokinetics in Age, Disease and Others	33
2.9.3	Dose Finding/Determination of Dosing Regimens	33
2.9.4	Individualized Dosing and Therapeutic Drug Monitoring	34
2.10	Conclusions	34
	References	34

### **3 Principles and Methods of the Pharmaceutical Drug Discovery Process – From Idea over Target to a Development**

#### **Candidate** 37

*Werner Kramer*

Summary 37

3.1	What is the Purpose of Drug Discovery?	38
3.2	Phases of the Drug Discovery Process	38
3.3	Target Identification	40
3.3.1	What is a Pharmaceutical Target?	40
3.3.2	Sources for Target Identification	41
3.3.2.1	An Extensive Inquiry of All Published Data on a Particular Target and Its Pathway(s)	41
3.3.2.2	(Pharmaco)-Genetic Links to a Phenotype	41
3.3.2.3	Phenotypic Screening	41
3.3.3	Target Validation	42
3.3.3.1	Genetic Target Validation	42
3.3.3.2	Chemical Target Validation ('Chemical Genomics')	42
3.4	Strategies to Modulate Biological Targets	43

3.4.1	Preventing Formation of the Target Protein	43
3.4.2	Targeting the Ligand Binding Site of the Protein	44
3.4.3	Targeting Protein–Protein Interactions (PPI)	44
3.4.4	Masking Proteins	44
3.5	The Lead Identification Process	44
3.6	Strategies to Identify Lead Compounds	45
3.6.1	High-Throughput Screening (HTS)	45
3.6.1.1	Assay Criteria for Screening Approaches	47
3.6.1.2	Structure-Based Rational Drug Design	49
3.6.1.3	Phenotypic Screening	51
3.6.2	Chemical Libraries	52
3.6.2.1	Criteria for the Compounds in a Chemical Library	53
3.6.2.2	DNA-Encoded Chemical Libraries (DEL Libraries)	54
3.7	Drug Candidates	55
3.7.1	Lead Optimization and Candidate Selection	56
3.8	Outlook	59
	References	60
<b>4</b>	<b>Biomarkers: Definitions and Utility for Drug Development</b>	<b>63</b>
	<i>Dominik Hartl</i>	
	Summary	63
4.1	Introduction	64
4.2	Biomarker Modalities	69
4.2.1	Molecular Biomarkers	71
4.2.2	Imaging Biomarkers	72
4.2.3	Digital Biomarkers	73
4.3	Biomarkers in Drug Development	73
4.4	Biomarker Use Cases	75
4.5	Outlook	78
	References	78
<b>5</b>	<b>Toxicology in Drug Development – Understanding a Drug’s Toxicity and Managing Safety and Risks</b>	<b>81</b>
	<i>Elisabeth Rosner</i>	
	Summary	81
5.1	Introduction to Toxicology and Definitions	82
5.2	The General Toxicological Framework	83
5.3	The Concept of the Therapeutic Index	84
5.4	The International Regulatory Framework for Safety Evaluations	85
5.4.1	The Data Package Required for First in Human (FIH) Trials	86
5.4.2	The Data Package Required for Studies Beyond FIH	87
5.4.2.1	The Data Package Required for Studies Beyond FIH for Large (Bio)molecules and Oncology Compounds	87
5.5	Animal Species Selection	89
5.6	Basic Concepts for Non-clinical Studies to Support Clinical Trials	89

5.7	What Activity at Which Stage of Development?	92
5.8	Estimating the Safe Starting Dose in FIH Trials	93
5.8.1	Anti-cancer Drugs	93
5.9	Toxicological Evaluations During Late-Stage Drug Development	94
5.10	Outlook	96
	References	97
<b>6</b>	<b>Introduction to Chemistry Manufacturing and Controls – From Compound and Development Candidate to Drug</b>	<b>99</b>
	<i>Thomas Eichinger</i>	
	Summary	99
6.1	CMC Introduction and Background	100
6.2	Some Basic Thoughts	100
6.2.1	Transition from Research to Development	100
6.2.2	Some Fundamentals About Physico-chemical Characteristics	101
6.2.3	The Biopharmaceutical Classification System (BCS)	102
6.2.4	Stability Investigations	104
6.2.5	The Physical Appearance: Morphology and Polymorphism	105
6.3	Preclinical Development and the Clinical Phase 1 from a CMC Perspective	107
6.3.1	The Active Pharmaceutical Ingredient (API)	107
6.3.2	The Drug Product	108
6.3.3	Analytical Development	109
6.3.4	Regulatory Green Light for FIH Study	110
6.4	Preclinical Development and the Clinical Phase 2 from a CMC Perspective	110
6.4.1	The Active Pharmaceutical Ingredient (API)	111
6.4.2	The Drug Product	111
6.4.3	Analytical Development	111
6.5	Preclinical Development and the Clinical Phase 3 from a CMC Perspective	111
6.6	The Compilation and Authoring of the Submission Dossier for Marketing Authorization	112
6.7	The NDA Submission and the Steps to Product Launch	116
	References	117
<b>7</b>	<b>Translational Medicine – The Bridging Discipline. Role and Tools in the Drug Development Process</b>	<b>119</b>
	<i>Markus Hinder and Dominik Hartl</i>	
	Summary	119
7.1	Translational Medicine, Definitions and History	120
7.2	The Translational Gap	122
7.2.1	Failed Translation: Why It Happens and Why We Need to Avoid It	122
7.2.2	Predictivity of Models and the Translatability Gap	123
7.2.3	The Learning and Confirming Paradigm	124

7.3	Paths of Translation	126
7.3.1	Forward vs Reverse/Back-Translation	126
7.4	Translational Medicine in Drug Development	129
7.4.1	Bench to Bedside and Back or Forward and Backward Translation	129
7.4.1.1	Examples of Classical Forward Translation	129
7.4.1.2	Examples of Bedside to Bench or Backward Translation	130
7.5	Serendipity	132
7.5.1	Serendipity Examples: Sildenafil and the SGLT2 inhibitors	133
7.6	Conclusions	134
	References	136
<b>8</b>	<b>Decision-Making: What are the Key Drivers Around Decision-Making in Drug Development?</b>	<b>139</b>
	<i>Nigel McCracken</i>	
	Summary	139
8.1	Background	140
8.1.1	Drug Development Process	140
8.1.2	Target Product Profile	141
8.2	Key Decision Points	142
8.3	Moving Towards ‘Go IND Enabling’	143
8.4	Moving Towards Go/No Go First in Human (FIH)	144
8.5	Moving Towards Go/No Go Phase 2	146
8.6	Moving Towards Go Confirmatory Development	148
8.7	Concluding Remarks	150
	References	150
<b>9</b>	<b>Clinical Drug Development – Clinical Characterization for Regulatory Approval</b>	<b>151</b>
	<i>Werner Seiz</i>	
	Summary	151
9.1	Clinical Drug Development, Definition, and Framework	152
9.2	The Different Stages of Clinical Development	153
9.3	The Basic Framework and Elements for Clinical Trials	155
9.4	The Clinical Study Protocol	156
9.5	Written Subject Information	156
9.6	Graphical Study Design and Schedule of Activities	156
9.7	Definition of Patient Population and Sample Size Calculation	160
9.8	Study Design	161
9.9	General Methods and Statistical Tools	163
9.9.1	Analysis Populations	163
9.9.2	Clinical Operations	163
9.10	Target Product Profile, Clinical Development Plan, and Other Documents During Development	166
9.11	Changing Environment: Sensors, Digitalization, and COVID-19 Pandemic	166

9.12	Key Studies During Clinical Development	167
9.12.1	First-In-Human Study	167
9.12.2	Mechanistic Study	169
9.12.3	Clinical Proof-of-Concept	169
9.12.4	Dose-Ranging Studies	170
9.12.5	Efficacy Studies	171
9.12.6	Specific Approaches – Adaptive Trial Designs	171
9.12.7	Oncology Trials	173
9.12.8	Basket, Umbrella, and Platform Trials	173
9.13	Advisory Boards, Steering Committees, Data and Safety Monitoring Boards	174
9.13.1	Advisory Boards	174
9.13.2	Steering Committees	174
9.13.3	Endpoint Adjudication Committees	174
9.13.4	Data Safety and Monitoring Boards/Data Monitoring Committee	174
9.14	Summary of Information	175
	References	175
<b>10</b>	<b>Regulatory Affairs – Communicating with Health Authorities</b>	
	<i>Hans-Juergen Fuelle and Valerie Lanctin</i>	
	Summary	177
10.1	Regulatory Environment – Getting Started	178
10.2	The Role of Regulatory Affairs in Early Drug Development	180
10.3	The Common Technical Document	182
10.4	Investigational New Drug	184
10.5	Clinical Trial Application	184
10.6	Early Consultations with Health Authorities	185
10.7	Regulatory Requirements for Paediatric Diseases	186
10.8	Regulatory Pathways for Drug Development for Orphan/Rare Diseases	187
10.9	Accelerated Pathways for Expedited Clinical Development and Regulatory Review	188
10.10	The Role of Regulatory Affairs in Late-Stage Drug Development	190
10.11	The Role of Regulatory Affairs Before, During and After Registration	194
10.12	Pre-submission Meetings with Health Authorities	195
10.13	Additional Submission-Enabling Regulatory Affairs Activities	196
10.14	Health Authority Review of Registration Dossiers	196
	References	200

<b>11</b>	<b>Regulatory Affairs in Device Development – How to Design Medical Devices Capable to Enter the Market</b>	<b>203</b>
	<i>Dietmar Schaffarczyk</i>	
	Summary	203
11.1	Introduction	204
11.2	Product Commercialization	206
11.3	Ten Things to Know and Consider When Developing a Device	208
11.4	Obtaining Qualified Input from Interested Parties	212
11.5	Planning and Executing All Important Development Milestones	216
11.6	Design and Development Verification: Did I MAKE the Product Right?	218
11.7	Design and Development Validation: Did I MAKE the Right Product?	219
	References	222
<b>12</b>	<b>Market Entry and Reimbursement: Making Drugs Available for Patients After Drug Approval</b>	<b>225</b>
	<i>Ahmad Bechara and Rola Haroun</i>	
	Summary	225
12.1	Introduction	226
12.2	Healthcare Challenges	226
12.3	What Does Market Access Mean?	227
12.4	Market Access Gatekeepers	228
12.5	Drug Purchasing	228
12.6	Payers and Value Assessment	229
12.7	Health Economics as a Decision Tool for Market Access	231
12.7.1	What Is Health Economics?	232
12.7.2	What Is the Aim of a HTA?	232
12.7.3	HTA Process	233
12.8	Setting the Right Price	234
12.8.1	Pricing Policy	234
12.8.2	Therapeutic Reference Pricing (Internal)	234
12.8.3	International/External Reference Pricing	235
12.8.4	Value-Based Pricing	235
12.8.5	Overview of the Pricing and Reimbursement Process in Key European Markets	236
12.9	How Does the Pharma Industry Prepare for Market Entries?	237
12.10	Early Patient Access	240
12.11	Managed Entry Agreements	240
12.12	Market Access Trends	242

12.12.1	USA and Canada	242
12.12.2	Europe	242
12.13	Future Market Access Challenges	243
	References	243
<b>13</b>	<b>Pricing in Germany – Key Learnings for Optimizing Price Potential After the Introduction of AMNOG</b>	<b>247</b>
	<i>Jacqueline Jones</i>	
	Summary	247
13.1	Introduction	247
13.2	Structure of the Pricing and Reimbursement Process in Germany	249
13.3	Analysis of Effects of the AMNOG Process on Drug Prices in Germany	251
13.4	Learnings from AMNOG to Ensure Success in the German Market	253
13.5	Study Design	254
13.6	Dossier Preparation	254
13.7	Pre-launch Strategy	254
13.8	Post-launch	255
13.9	Price Negotiation	255
13.10	Post-negotiation	255
13.11	Key Takeaways	256
	Key Resources	256
	References	256
<b>14</b>	<b>Project, Risk, and Portfolio Management – Managing R&amp;D Projects Today</b>	<b>257</b>
	<i>Alexander Schuhmacher and Markus Hinder</i>	
	Summary	257
14.1	Introduction	258
14.2	The Phases of the Pharma R&D Process	259
14.3	Projects and Project Management	263
14.4	Project Life Cycle and Project Phases	270
14.5	Risk Management	272
14.6	Portfolio Management	274
	References	279
<b>15</b>	<b>Intellectual Property – How to Protect Innovation in the Biopharmaceutical Industry</b>	<b>281</b>
	<i>Charles E. Jeffries and Karen D. Larbig</i>	
	Summary	281
15.1	Introduction to Intellectual Property Rights	282
15.2	Patent Rights	284
15.2.1	What is a Patent?	284
15.2.2	Patentability Criteria	285
15.2.3	Why and How to Apply for a Patent?	286



15.2.4	Patenting Procedure	287
15.2.4.1	From Invention Harvesting to Patent Filing	287
15.2.4.2	Patent Prosecution and Grant Procedure	288
15.2.5	Value and Use of Patent Rights	291
15.3	The 'Freedom to Operate' Principle	292
15.4	Intellectual Property Protection in the Biopharmaceutical Industry	294
15.4.1	Patent Protection for a Pharmaceutical Drug Product	296
15.4.2	Life Cycle Management	298
15.4.3	Patent Term Extensions	298
15.4.4	Regulatory Data Protection	299
15.4.5	Loss of Exclusivity	299
15.4.6	FTO Issues in the Biopharmaceutical Industry	300
15.4.7	Role of an In-house Intellectual Property Department	301
15.5	Conclusion	302
	Key Resources	302
<b>16</b>	<b>Patents in the Biomedical Sciences and Industry – The Case of the Swiss Life Science Company Prionics</b>	<b>305</b>
	<i>Martin A. Bader and Oliver Gassmann</i>	
	Summary	305
16.1	Patents in the Biomedical Sciences and Industry	306
16.2	The Swiss Life Science Company Prionics	309
16.3	Success Factors and Failures	312
16.4	Consequences and Insights	313
	Key Resources	314
	References	314
<b>17</b>	<b>Pharmaceutical Business Development and Licensing – Overview of a Cross-Functional and Multifaceted Role and Its Key Elements in Biopharmaceutical Industry</b>	<b>317</b>
	<i>Monika Schuessler</i>	
	Summary	317
17.1	Introduction	318
17.2	Types of Collaborations	318
17.3	Licensing Agreements	319
17.4	Commercial or Distribution Partnerships	320
17.5	Research Collaborations	321
17.6	Other Types of Agreements	321
17.7	Tech Transfer Agreements	322
17.8	Structured Approach – How to Start a Transaction?	322
17.9	Evaluation Process	324
17.10	Due Diligence	327
17.11	Letter of Intent and Term Sheet	329
17.12	Negotiation and Contract Closure	330
17.13	Alliance Management	331

17.14	Conclusions	332
	References	332
<b>18</b>	<b>The Entrepreneur's Guide Through the Galaxy of Biotech Funding</b>	<b>333</b>
	<i>Mathias Schmidt</i>	
	Summary	333
18.1	Introduction	334
18.2	Seed Funding – from a Research Concept to Validation of a Business Idea	335
18.3	Getting Serious – Series A	336
18.3.1	Valuation	338
18.3.2	Building the Team	338
18.3.3	Alternatives to Venture Financing	338
18.4	Getting more Serious – Series B	339
18.5	Venture Debt as an Alternative to a Series B	341
18.6	Getting most Serious – Series C	341
18.7	Exit Options	342
18.8	Closing Remarks	343
	Reference	343
<b>19</b>	<b>Medical Technologies – Key Learning from Two Case Studies</b>	<b>345</b>
	<i>Günter Lorenz and Andreas Schüle</i>	
19.1	Case Study 1 – Medical Grade Plastics (MPG)	345
19.1.1	Consistency of Formulation	347
19.1.2	Security of Supply	348
19.1.3	Appendix – ISO 10993	349
19.2	Case Study 2 – Vitrectomy Using Fast Pneumatic-Driven Cutter Systems	350
19.3	Innovative Valve Technology	352
19.4	Integration Technology	353
<b>20</b>	<b>Laboratory Diagnostics – Tools for Clinical Decision-Making and Clinical Trial Endpoints</b>	<b>357</b>
	<i>Bhuvnesh Agrawal</i>	
	Summary	357
20.1	Definition of Diagnostics, Why Diagnostics, Importance of Diagnostics, Sample Types	358
20.2	The Diagnostics Industry – Key Figures and Key Players	361
20.3	Brief History of Diagnostics	362
20.4	Elements of the Laboratory Workflow (Pre-analytics, Analytics, and Post-analytics)	362
20.5	Various Types of Diagnostic Tests in the Laboratory	363
20.5.1	Clinical Chemistry	363

20.5.2	Immunology	364
20.5.3	Haematology and Coagulation	364
20.5.4	Microbiology	365
20.5.5	Molecular Diagnostics	365
20.5.6	Histopathology	366
20.6	Place of Diagnostics in the Clinical Workflow	366
20.7	Quality Management	367
20.7.1	Commercial Tests	367
20.7.2	Laboratory-Developed Tests (LDTs)	367
20.7.3	Test Performance Characteristics	369
20.8	Regulatory Approval of Diagnostics	370
20.9	The Diagnostics R&D Process – Stage Gate and Agile Development Processes	373
20.9.1	The Stage-Gate Process	373
20.9.2	The Agile Development Process	373
20.10	The Future of Diagnostics – Key Technologies and Trends, Personalized Diagnostics	375
20.10.1	Automation	375
20.10.2	Molecular Testing	375
20.10.3	Personalized/Precision Medicine	375
20.10.4	Point of Care Testing	375
20.10.5	Digitization and Artificial Intelligence	376
20.11	Conclusions	376
	References	376
<b>21</b>	<b>Vaccination: Towards an Improved Influenza Vaccine</b>	<b>377</b>
	<i>Pierre A. Morgon</i>	
	Summary	377
21.1	Influenza – A Deadly Disease with a Long History	378
21.2	The Annual Challenge	383
21.3	Mechanisms of the Immune Response	384
21.4	Antigen Content	385
21.5	Although Influenza Vaccine Formulation Evolves to Reflect the Circulating Strains, Innovation is Rare	386
21.6	Medical Rationale for Intradermal Administration (ID)	386
21.7	Search for Greater Acceptability	387
21.8	Acceptability of the New Device	389
21.9	Acceptability in Real Life	391
21.10	Outlook and Trends	393
	References	394
	<b>Index</b>	<b>397</b>

